RazelleKurzrockMD

Chief, Division of Hematology & Oncology Sr. Deputy Center Director, Clinical Science, Director, Center for Personalized Cancer Therapy and Clinical Trials Office, UC San Diego Moores Cancer Center

Join to view full profile

Dr. Kurzrock is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Kurzrock's full profile

Already have an account?

Office
3855 Health Sciences Dr
La Jolla, CA 92093
Phone+1 858-822-5182

Fax+1 858-534-2180
Is this information wrong?

Education & Training

University of Texas Health Science Center at HoustonResidency, Internal Medicine, 1982 - 1983
Tulane UniversityResidency, Internal Medicine, 1979 - 1981
University of Toronto Faculty of MedicineClass of 1978

Certifications & Licensure

FL State Medical License 2021 - Present
NY State Medical License 1986 - Present
WI State Medical License 2022 - 2025
CA State Medical License 2014 - 2025
TX State Medical License 1984 - 2024
LA State Medical License 1979 - 1984
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Elected Member The American Society for Clinical Investigation, 1997

Clinical Trials

Amifostine in Treating Patients With Myelodysplastic Syndrome Start of enrollment: 1997 Jun 05
Completed
Phase 2
Tipifarnib in Treating Patients With Myelodysplastic Syndromes Start of enrollment: 2002 Jun 01
Completed
Phase 1
PEG-Intron For Chronic Myelogenous Leukemia Patients Unresponsive To Or Intolerant Of Roferon Or Intron Start of enrollment: 2001 Feb 01
Terminated
Phase 2
A Study Of Deoxycoformycin(DCF)/Pentostatin In Lymphoid Malignancies Start of enrollment: 1994 Sep 06
Completed
Phase 2
Phase II Study Of Roferon and Accutane For Patients With T-Cell Malignancies Start of enrollment: 1990 May 08
Completed
Phase 2
Imatinib Mesylate in Treating Patients With Stage IV Colorectal Cancer Start of enrollment: 2002 May 01
Completed
Phase 2
Tipifarnib and Sorafenib Tosylate in Treating Patients With Biopsiable Advanced Cancer Start of enrollment: 2005 Oct 01
Completed
Phase 1
Study of Atiprimod Treatment for Patients With Advanced Cancer Start of enrollment: 2005 Mar 01
Terminated
Phase 1
Azacytidine and Valproic Acid in Patients With Advanced Cancers Start of enrollment: 2005 May 01
Completed
Phase 1
Phase I Trial of ZIO-101 in Patients With Solid Tumors Start of enrollment: 2005 May 01
Completed
Phase 1
A Phase I, Study to Evaluate the Safety and Tolerability of Intravenous EZN-2208 in Patients With Advanced Solid Tumors or Lymphoma (EZN-2208-01) Start of enrollment: 2007 May 01
Completed
Phase 1
Bevacizumab and Temsirolimus in Patients With Advanced Malignancy Start of enrollment: 2008 Jan 25
Completed
Phase 1
Study of Temsirolimus, Topotecan, and Bortezomib Start of enrollment: 2008 Sep 01
Completed
Phase 1
Phosphatidylinositol 3 Kinase and Mammalian Target of Rapamycin (PI3K-mTOR) in Advanced Cancer Patients Start of enrollment: 2009 Apr 01
Terminated
Phase 1, Phase 2
FLT-PET as an Imaging Biomarker With Temsirolimus, Topotecan, and Bortezomib Start of enrollment: 2010 Jun 01
Completed
Phase 1
Temsirolimus In Phase 0 Start of enrollment: 2010 Aug 01
Completed
Early Phase 1
Phase 1 Trial With SIR-Spheres and Cetuximab +/- Erlotinib Start of enrollment: 2012 Dec 01
Withdrawn
Phase 1
Survival Prolongation by Rationale Innovative Genomics Start of enrollment: 2017 Nov 29
Terminated
Phase 1, Phase 2
The Registry of Oncology Outcomes Associated With Testing and Treatment Start of enrollment: 2021 May 05
Recruiting
Join now to see all

Publications & Presentations

PubMed

Evolution of Precision Oncology, Personalized Medicine, and Molecular Tumor Boards.
Fujiwara, Y., Kato, S., Kurzrock, R.> ;Surgical Oncology Clinics of North America. 2024 Apr 1
OX40/OX40 ligand and its role in precision immune oncology.
Daisuke Nishizaki, Suzanna Lee, Mary K Nesline, Rebecca A Previs, Jeffery M Conroy, Paul DePietro, Sarabjot Pabla, Bicky Thapa, Shumei Kato, Hirotaka Miyashita, Razell...> ;Cancer Metastasis Reviews. 2024 Mar 25
Outcome differences by sex in oncology clinical trials.
Ashwin V Kammula, Alejandro A Schäffer, Padma Sheila Rajagopal, Eytan Ruppin, Razelle Kurzrock> ;Nature Communications. 2024 Mar 23
If it's a target, it's a pan-cancer target: Tissue is not the issue.
Jacob J Adashek, Shumei Kato, Jason K Sicklick, Scott M Lippman, Razelle Kurzrock> ;Cancer Treatment Reviews. 2024 Apr 1
Tumor-agnostic baskets to N-of-1 platform trials and real-world data: Transforming precision oncology clinical trial design.
Elena Fountzilas, Apostolia-Maria Tsimberidou, Henry Hiep Vo, Razelle Kurzrock> ;Cancer Treatment Reviews. 2024 Apr 1
An Autobiographical Case Series of Familial Post Ambulatory Swollen Hands (POTASH): Hand Swelling in a Man and His Sister While Participating in a Half Marathon.
Philip R Cohen, Bonnie S Cohen, Razelle Kurzrock> ;Cureus. 2024 Mar 1
SWOG 1609 cohort 48: anti-CTLA-4 and anti-PD-1 for advanced gallbladder cancer.
Guadarrama, E., Ferri, W., Othus, M., Lopez, G., Patel, S., Chae, Y., Dennis, M., Powers, B., Liao, C., George, T., Sharon, E., Ryan, C., Blanke, C., Kurzrock, R.> ;Cancer. 2024 Feb 15
Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3β Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies.
Davis, E., Benedito A Carneiro, Ludimila Cavalcante, Devalingam Mahalingam, Anwaar Saeed, Howard Safran, Wen Wee Ma, Andrew L Coveler, Steven Powell, Bruno Bastos, Eli...> ;Clinical Cancer Research. 2024 Feb 1
Transcriptomic-Based Microenvironment Classification Reveals Precision Medicine Strategies for Pancreatic Ductal Adenocarcinoma.
Ben George, Olga Kudryashova, Andrey Kravets, Samih Thalji, Subramaniam Malarkannan, Razelle Kurzrock, Ekatherina Chernyavskaya, Mariia Gusakova, Dmitry Kravchenko, Dm...> ;Gastroenterology. 2024 Jan 25
Correlation between tumor size change and outcome in a rare cancer immunotherapy basket trial.
Othus, M., Chae, Y., Dietrich, E., Streicher, H., Patel, S., Sharon, E., Kurzrock, R.> ;Journal of the National Cancer Institute. 2024 Jan 18
Navigating between Scylla and Charybdis: A roadmap to do better than Pola-RCHP in DLBCL.
Deshpande, A., Munoz, J., Rimsza, L., Nowakowski, G., Kurzrock, R.> ;Cancer Treatment Reviews. 2024 Mar 1
A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609 Cohort 47) in Patients with Gestational Trophoblastic Neoplasia.
Megan Othus, David Mutch, Wolfram Samlowski, Elad Sharon, Gabby Lopez, Melissa Plets, Patel, S., Chae, Y., Dennis, M., Gordon, S., Robinson, W., Ryan, C., Blanke, C., ...> ;Clinical Cancer Research. 2024 Jan 5
Critical insights into the evolving drug-approval process in China.
Nikanjam, M., Kurzrock, R.> ;Cancer. 2024 Mar 1
High CTLA-4 transcriptomic expression correlates with high expression of other checkpoints and with immunotherapy outcome.
Krishnamurthy, N., Nishizaki, D., Nesline, M., Pabla, S., Conroy, J., DePietro, P., Lippman, S., Miyashita, H., Kato, S., Kurzrock, R.> ;Therapeutic Advances in Medical Oncology. 2024 Jan 1
Pan-cancer analysis of TIM-3 transcriptomic expression reveals high levels in pancreatic cancer and interpatient heterogeneity.
Lim, J., Nishizaki, D., Lee, S., Pabla, S., Nesline, M., Conroy, J., DePietro, P., Kurzrock, R., Miyashita, H., Adashek, J., Lippman, S., Kato, S.> ;Cancer Medicine. 2023 Dec 22
2 citations
Considering molecular alterations as pan-cancer tissue-agnostic targets.
Sicklick, J., Adashek, J., Kato, S., Lippman, S., Kurzrock, R.> ;Nature Cancer. 2023 Dec 1
1 citations
Overcoming Immune Checkpoint Therapy Resistance with SHP2 Inhibition in Cancer and Immune Cells: A Review of the Literature and Novel Combinatorial Approaches.
Alireza Tojjari, Anwaar Saeed, Arezoo Sadeghipour, Razelle Kurzrock, Ludimila Cavalcante> ;Cancers. 2023 Nov 13
Revolutionizing cancer drug development: Harnessing the potential of basket trials.
Vivek Subbiah, Howard A Burris 3rd, Razelle Kurzrock> ;Cancer. 2024 Jan 1
Cancer-Immunity Marker RNA Expression Levels across Gynecologic Cancers: Implications for Immunotherapy.
Jessica Jou, Shumei Kato, Hirotaka Miyashita, Kartheeswaran Thangathurai, Sarabjot Pabla, Paul DePietro, Mary K Nesline, Jeffrey M Conroy, Eitan Rubin, Ramez N Eskande...> ;Molecular Cancer Therapeutics. 2023 Nov 1
1 citations
Development of a blood-based extracellular vesicle classifier for detection of early-stage pancreatic ductal adenocarcinoma.
Juan Pablo Hinestrosa, Rosalie C Sears, Harmeet Dhani, Jean M Lewis, Gregor Schroeder, Heath I Balcer, Dove Keith, Brett C Sheppard, Razelle Kurzrock, Paul R Billings> ;Communications Medicine. 2023 Oct 19
2 citations
MyPathway Human Epidermal Growth Factor Receptor 2 Basket Study: Pertuzumab + Trastuzumab Treatment of a Tissue-Agnostic Cohort of Patients With Human Epidermal Growth...
Christopher J Sweeney, John D Hainsworth, Ron Bose, Howard A Burris, Razelle Kurzrock, Charles Swanton, Claire F Friedman, David R Spigel, Tania Szado, Katja Schulze, ...> ;Journal of Clinical Oncology. 2024 Jan 20
5 citations
ALK fusions in the pan-cancer setting: another tumor-agnostic target?
Aditya Shreenivas, Filip Janku, Mohamed A Gouda, Hui-Zi Chen, Ben George, Shumei Kato, Razelle Kurzrock> ;NPJ Precision Oncology. 2023 Sep 29
At the right dose: personalised (N-of-1) dosing for precision oncology.
Mina Nikanjam, Shumei Kato, Jason K Sicklick, Razelle Kurzrock> ;European Journal of Cancer. 2023 Nov 1
Exceptional Response to MEK Inhibition in a Patient With RAF1-Mutant Myxofibrosarcoma: Case Report and Mechanistic Overview.
Özgü, E., Aydin, E., Adibi, A., Tokat, Ü., Tutar, O., Hu, J., Demiray, I., Demiray, M., Kurzrock, R.> ;JCO Precision Oncology. 2023 Sep 1
Increased KRAS G12C Prevalence, High Tumor Mutational Burden, and Specific Mutational Signatures Are Associated With MUTYH Mutations: A Pan-Cancer Analysis.
Umut Disel, Smruthy Sivakumar, Tim Pham, Zoe Fleischmann, R I Anu, Ethan S Sokol, Razelle Kurzrock> ;The Oncologist. 2024 Feb 2
Join now to see all

Journal Articles

International, Evidence-Based Consensus Treatment Guidelines for Idiopathic Multicentric Castleman Disease
Aaron Goodman, Corey Casper, Sudipto Mukherjee, Peter Voorhees, Angela Dispenzieri, David C Fajgenbaum, Amy Chadburn, Razelle Kurzrock, Raj Jayanthan, Sunita Nasta, Th..., Blood
Preoperative Circulating Tumor DNA in Patients with Peritoneal Carcinomatosis Is an Independent Predictor of Progression-Free Survival
Andrew M Lowy, Kaitlyn J Kelly, Joel M Baumgartner, Lisa Tran, Razelle Kurzrock, Annals of Surgical Oncology

Abstracts/Posters